0001213900-19-012450.txt : 20190710 0001213900-19-012450.hdr.sgml : 20190710 20190710172139 ACCESSION NUMBER: 0001213900-19-012450 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190628 FILED AS OF DATE: 20190710 DATE AS OF CHANGE: 20190710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pearson Mark E. CENTRAL INDEX KEY: 0001486558 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14778 FILM NUMBER: 19950009 MAIL ADDRESS: STREET 1: 3031 TISCH WAY STREET 2: SUITE 505 CITY: SAN JOSE STATE: CA ZIP: 95128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE B-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 4 1 ownership.xml X0306 4 2019-06-28 0 0000812796 SOLIGENIX, INC. SNGX 0001486558 Pearson Mark E. 29 EMMONS DRIVE, SUITE B-10 PRINCETON NJ 08540 1 0 1 0 Common Stock 2019-06-28 4 A 0 78338 0.71 A 78338 I See footnote Common Stock 2500000 D These securities were issued in lieu of cash compensation payable for services rendered, with the number of shares issued being calculated based upon the closing price of $0.71 on June 28, 2019. The transaction is exempt under Rule 16b-3 of the Securities Exchange Act of 1934. These securities are held by Altamont Pharmaceutical Holdings, LLC, a company for which the reporting person serves as general partner and chief executive officer. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or any other purpose. /s/ Mark E. Pearson 2019-07-10